Regeneron: Phase 3 Trial Of Dupixent In Children With Eosinophilic Esophagitis Meets Main Goal

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF,SNY) said that a phase 3 trial, which assessed the investigational use of Dupixent or dupilumab in children aged 1 to 11 years with eosinophilic esophagitis, met its primary endpoint of histological disease remission at 16 weeks with both higher and lower dose weight-tiered regimens.

In the phase 3 trial, 102 children aged 1 to 11 were randomized to receive Dupixent, in either a higher dose (n=37) or lower dose (n=31) regimen based on body weight, or placebo (n=34).

At 16 weeks, 68% of children on higher dose and 58% of patients on lower dose Dupixent achieved the primary endpoint of significant histological disease remission compared to 3% of children on placebo.

Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.

In May 2022, the U.S. Food and Drug Administration approved Dupixent 300 mg weekly to treat patients with eosinophilic esophagitis aged 12 years and older and weighing at least 40 kg after granting the medicine Priority Review.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Seffner, Florida -based Canyon Furniture Co. is recalling ladders sold with bunk bed and hutch sets citing entrapment and strangulation risks, the U.S. Consumer Product Safety Commission said. The about 2,100 units of Canyon Lake and Cottage Colors Bunk Bed and Hutch Sets were sold exclusively at Rooms To Go. Lyft announced the expansion to its partnership with Indeed in Jobs Access program. The ride-hailing company will be providing transportation access for Indeed's Ready to Work program. Indeed's Ready to Work program is a series of free virtual and in-person events for job seekers in several cities across the U.S. from September 15 to October 8, 2022. Pool and Spa drain covers imported to the United States by various companies have been recalled due to violation of the Virginia Graeme Baker Pool and Spa Safety Act, the U.S. Consumer Product Safety Commission announced. The various recalls include pool and spa drain covers manufactured in China and sold exclusively at Amazon.com for different prices ranging from $10 to $12.
Follow RTT